News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Health Canada Removes Novartis Pharmaceuticals Canada Inc. (NVS)'s Cox-2 Drug Prexige from the Market over Liver Problems


10/4/2007 1:21:42 PM

TORONTO - Health Canada has ordered the anti-inflammatory drug Prexige off the market, citing the potential for serious liver-related adverse events. In a release, the department said it was stopping sales and would cancel market authorization for lumiracoxib, which is sold by Novartis Pharmaceuticals Canada Inc. as Prexige. In a statement posted on its website, the company said it will comply with Health Canada's request.

Read at Canadian Press
Read at CBC


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES